Commissioner Marty Makary signed off on the plan to push out the agency’s top vaccine official, Peter Marks, in one of his first acts as chief,

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

The pharma and biotech sector has been under pressure since Donald Trump returned to the White House earlier this year.

Moderna stock dips 10% amid FDA resignation, signaling regulatory risks. Strong cash reserves can't offset competitive and mRNA challenges. Learn more on MRNA stock here.

Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews vaccines, resigned on Friday.

Kennedy Jr., a longtime and visceral critic of pharmaceutical and biotech companies, was nominated by President Trump to be the nation’s health secretary, the head of biotech’s largest trade group issued a statement saying that he had “every confidence” that the industry would “continue to thrive and deliver” on its goals,